AI Analysis | Feedback

• An Intuitive Surgical (makers of da Vinci surgical robots) for heart arrhythmia ablation procedures.
• A specialized Medtronic, focused on advanced tools for safer and more precise heart arrhythmia ablation.
• A disruptive competitor to Johnson & Johnson's heart ablation technology.

AI Analysis | Feedback

• VIVO™ System: A non-fluoroscopic, radiation-free cardiac ablation navigation system designed to improve patient safety and procedural efficiency.
• Lock-It™ System: A catheter stabilization system intended to provide precise control and consistent catheter positioning during electrophysiology procedures.
• Precision IR™: A device used to guide optimal catheter tip-to-tissue contact force during cardiac ablation procedures.

AI Analysis | Feedback

AI Analysis | Feedback

AI Analysis | Feedback

David Jenkins, Executive Chairman of the Board, Chief Executive Officer, and Chief Commercial Officer

David Jenkins has over thirty years of experience in the medical device field, primarily with small companies. He previously operated two other cardiac electrophysiology companies, Arrhythmia Research Technology, Inc. and EP MedSystems, Inc., as CEO and Chairman. He also founded Transneuronix, Inc., a company in the implantable neurostimulator market focused on obesity and weight loss. Jenkins has a history of successful company exits, including EP MedSystems, Inc. to St. Jude Medical (now owned by Abbott) in 2008 and Transneuronix to Medtronic in 2005. He also founded Catheter Precision and has personally invested approximately $30 million into the company.

Philip Anderson, Chief Financial Officer and Principal Accounting Officer

Philip Anderson was appointed Chief Financial Officer effective January 6, 2025. He previously served as Chief Financial Officer for Heritage Distilling Corporation (August 2021 - November 2022), Crown Electrokinetics Corp. (August 2020 - June 2021), and Kubient, Inc. (June 2019 - January 2020). Before these roles, he was a hedge fund partner for 17 years, specializing in investments in small and microcap companies.

Margrit Thomassen, Controller and Secretary

Margrit Thomassen has been a full-time employee at the Catheter Precision subsidiary since 2019 and has served as Controller for the company since the acquisition of Catheter Precision by Ra Medical in January 2023. She also served as Interim Chief Financial Officer as of January 2, 2024.

Marie-Claude Jacques, Chief Commercialization Officer

Marie-Claude Jacques previously headed up US sales at Baylis and subsequently served as Vice President at Boston Scientific, Inc., within their cardiac electrophysiology division.

Missiaen Huck, Chief Operating Officer

Missiaen Huck is listed as the Chief Operating Officer of Catheter Precision.

AI Analysis | Feedback

The key risks for the public company Catheter Precision (VTAK) are primarily centered around its precarious financial health, regulatory hurdles, and risks associated with its financing strategies.

1. Financial Health and Risk of Bankruptcy: Catheter Precision faces significant financial challenges, indicated by a very low Altman-Z score of -18.07, suggesting a high risk of bankruptcy. The company has consistently reported negative earnings and cash flow from operations, and its short-term assets are insufficient to cover short-term and long-term liabilities. Furthermore, the company has less than a year of cash runway based on its current free cash flow, raising concerns about its ability to fund ongoing operations.
2. Regulatory Uncertainty: As a medical technology company, Catheter Precision's growth narrative is heavily dependent on regulatory approvals. Delays or rejections for FDA approval of its CPNS System could collapse its growth plans.
3. Shareholder Dilution and Financing Risks: The company has engaged in financing strategies, such as private placements and the issuance of warrants, which pose risks of significant shareholder dilution. The conversion of preferred stock and warrants is often contingent on shareholder approval, which could delay or even scuttle crucial deals, impacting the company's financial stability. The number of shares outstanding has increased dramatically in the past year, indicating substantial dilution.

AI Analysis | Feedback

The clear emerging threat for Catheter Precision (VTAK) is the rapid development and increasing adoption of Pulsed Field Ablation (PFA) technology by larger, established medical device competitors such as Johnson & Johnson, Medtronic, Abbott, and Boston Scientific. These companies are actively launching and gaining regulatory approvals for comprehensive PFA systems that often include integrated mapping and navigation capabilities.

As PFA gains market share as a potentially safer and more efficient alternative to traditional radiofrequency or cryoablation for conditions like atrial fibrillation, and as these PFA systems offer increasingly sophisticated integrated mapping, they could diminish the need for or value proposition of standalone mapping and navigation systems like VTAK's VIVO, particularly if VIVO cannot demonstrate substantial complementary benefits or seamless integration with leading PFA platforms.

AI Analysis | Feedback

Catheter Precision (symbol: VTAK) operates in the field of cardiac electrophysiology (EP), offering products for diagnosing and treating cardiac arrhythmias. Their main products include the View into Ventricular Onset (VIVO) System, LockeT, and the Amigo Remote Catheter System.

• VIVO System (3D Cardiac Mapping for Ventricular Arrhythmias): The VIVO system is a non-invasive imaging system for 3D cardiac mapping to localize the sites of origin of idiopathic ventricular arrhythmias. The global market for 3D cardiac mapping systems was estimated at approximately USD 1.93 billion in 2024 and is predicted to grow to about USD 3.79 billion by 2034, exhibiting a compound annual growth rate (CAGR) of roughly 8.80% from 2025 to 2034. North America is projected to hold a dominant share of this market due to the increasing prevalence of cardiac arrhythmias, improved healthcare infrastructure, and robust reimbursement policies. The global ventricular tachycardia (VT) ablation market is also poised for growth from 2025 to 2034, with North America dominating with a 41% share in 2024. The global market for ventricular tachycardia devices is expected to reach $20.7 billion by 2033.

• LockeT (Suture Retention Device): LockeT is a suture retention device used for wound healing. The global suture retention device market is projected to reach $2.5 billion by 2025, exhibiting a CAGR of 7% from 2019 to 2033. More broadly, the global wound closure devices market was estimated at USD 14.43 billion in 2024 and is projected to reach USD 21.15 billion by 2030, growing at a CAGR of 6.60% from 2025 to 2030. The sutures segment dominated the wound closure devices market with a 42.5% revenue share in 2024. The global sutures market, encompassing devices like LockeT, was valued at USD 4.47 billion in 2024 and is expected to reach USD 7.46 billion by 2032.

• Amigo Remote Catheter System (Robotic Catheter Systems in Electrophysiology): This system falls under the broader category of robotic catheterization systems or electrophysiology robotic catheter navigation. The global electrophysiology robotic catheter navigation market size in 2024 stands at USD 865 million and is projected to expand at a CAGR of 13.2% from 2025 to 2033, reaching an estimated value of USD 2.58 billion by 2033. Similarly, the global robotic catheterization systems market is projected to rise from an estimated value of USD 54.4 million in 2025 to USD 189.6 million by 2035, advancing at a CAGR of 13.3%.

Overall, the global electrophysiology devices market, which encompasses many of Catheter Precision's offerings, was valued at USD 15.09 billion in 2025 and is expected to reach USD 52.55 billion by 2034, at a CAGR of 14.88%. North America holds the largest share in this market, accounting for 49.46% in 2024.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Catheter Precision (VTAK) over the next 2-3 years:

1. Increased Market Penetration and Adoption of Existing Products (LockeT and VIVO): Catheter Precision is actively expanding its customer base within existing markets. The company reported a pipeline of 87 potential hospital customers in Q3 2024, with 32 institutions in the evaluation phase, which further increased to approximately 50 hospitals evaluating VIVO and LockeT devices by Q1 2025. This expanding interest is translating into increased sales, with LockeT sales in Q2 2025 outpacing Q2 2024 sales by 200%. Several U.S. hospitals are projected to issue over $100,000 in purchase orders for LockeT by the end of 2025. The recruitment and onboarding of U.S. sales and clinical support personnel are also underway to bolster the national launch of LockeT and further expand VIVO's presence.
2. International Market Expansion, particularly in Europe: Catheter Precision is strategically expanding its geographic footprint. The LockeT device received CE Mark approval, enabling its sale in Europe, with a planned European launch in Q2 2025. The company has secured a new distributor in Italy and anticipates additional distributors in Spain, Portugal, and the UK. Furthermore, VIVO procedures are being scheduled or are ongoing in several European countries, including Germany, Turkey, France, Switzerland, and Italy, among others. International tender wins and purchase orders, such as the first purchase order in Croatia in September 2025 and a distribution agreement in Switzerland in October 2025, indicate growing momentum outside the U.S.
3. New Product Development and Strategic Acquisitions: The company is focused on enhancing its product portfolio through both internal development and strategic acquisitions. In Q1 2025, Catheter Precision acquired Cardionomics' assets, including their Cardiac Pulmonary Nerve Stimulation System, and PeriKard LLC, which are expected to contribute to future revenue streams. The company also received FDA 510(k) clearance for the Vertex catheter, an innovative intravascular device with Transforming Fixation technology that allows for on-demand shifts between flexible and firm states during endovascular procedures.
4. Positive Clinical Validation and Enhanced Product Awareness: Ongoing and promising clinical studies for both LockeT and VIVO are crucial for driving adoption and market acceptance. The LockeT study has shown positive hemostasis outcomes, and the VIVO platform has demonstrated a 94% accuracy rate. Catheter Precision actively participates in professional medical symposia to present these strong clinical results, which increases product awareness among medical professionals. A key opinion leader is also scheduled to demonstrate LockeT during an Italian symposium, further raising its profile in new markets.

AI Analysis | Feedback

Share Issuance

• On August 15, 2025, Catheter Precision implemented a 1-for-19 reverse stock split, reducing its outstanding common shares from approximately 23.3 million to about 1.7 million.
• Stockholders approved an increase in the number of authorized common shares from 60 million to 500 million on October 10, 2025.
• In September 2024, the company closed a $3.6 million underwritten public offering, issuing common stock units and pre-funded warrant units.
• On May 12, 2025, Catheter Precision completed a $1.5 million private placement equity financing through the sale of Series B Preferred Stock and warrants to institutional investors.

Inbound Investments

• Catheter Precision received $1.5 million in private placement equity financing from institutional investors on May 12, 2025.
• In the 24 months leading up to August 2025, institutional investors collectively purchased approximately $2.88 million worth of Catheter Precision stock, totaling 364,964 shares.
• The company raised $8.6 million in net cash from financing activities in 2024, which included proceeds from equity offerings and related party notes.

Outbound Investments

• On May 12, 2025, Catheter Precision acquired certain promissory notes of QHSLab, Inc. as part of a transaction that also included a $1.5 million private placement equity financing.

Capital Expenditures

• Between 2020 and 2025, Catheter Precision's reported capital expenditures (cash outflows) generally ranged from approximately $0.02 million to $0.27 million per period.